Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration agreement centered on the development of novel ophthalmic genetic therapy products, according to a press release. Avalanche’s AVA-101 is currently undergoing a phase 2a trial for wet age-related macular degeneration. Avalanche also has a proprietary adeno-associated virus-based gene therapy discovery and development technology called the Ocular BioFactory platform, according to the release.
ORLANDO, Fla. — A study here showed aflibercept to have superior efficacy and safety compared with grid laser photocoagulation at 24 weeks, according to the poster’s author. “The VIBRANT study showed the safety and efficacy of intravitreal aflibercept injections for the treatment of macular edema secondary to branch retinal vein occlusion,” David S. Boyer, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting.
ORLANDO, Fla. — The presence of vitreous separation may play a role in ranibizumab therapy for neovascular age-related macular degeneration, according to a poster presented at the Association for Research in Vision and Ophthalmology meeting here.Previous studies showed that bevacizumab injections in animal eyes had a slower rate of retinal penetration when the vitreous was attached to the anterior retina surface. The presence of vitreous separation may reduce the number of injections needed because of better retinal penetration or increase the number of injections needed because of less of the (Read more...)
Do adjunctive intravitreal corticosteroids help or hinder management of bacterial endophthalmitis? International Ophthalmology Clinics
Use of a fluoroquinolone antibiotic after cataract surgery was associated with a reduced rate of endophthalmitis, according to a large study. “In contrast, endophthalmitis was more likely to occur if timolol was used at the end of the procedure,” the study authors said. The retrospective case-control study included 75,318 eyes that underwent cataract surgery performed by 26 surgeons at four public hospitals and five surgical centers.
Bausch + Lomb entered an exclusive license agreement with Cirle Inc. for the three-dimensional Cirle Surgical Navigation System, the company announced in a news release. Bausch + Lomb is licensing the Cirle system for use in cataract surgery; the syste…